

REMARKS

In the Office Action, dated April 22, 2008 the Examiner had advanced a restriction requirement, requiring the Applicants to elect one of three groups of claims. The Examiner had grouped the claims as follows:

Group I: Claim 11.

Group II: Claim 12.

Group III: Claims 1, 3, 6-7, 10 and 14-18.

In response to the Office Action, dated April 22, 2008, Applicants elected without traverse the invention defined by Group III, which included claims 1, 3, 6-7, 10 and 14-18. Such election was made without prejudice to the non-elected claims in any related patent applications.

With respect to the elected group III, the Examiner had further required an election of a single disclosed specie of movement disorder. In response, the Applicants elected the movement disorder that comprises Parkinson's disease.

In the Office Communication, dated September 24, 2008, the Examiner states that the Applicants' election of the "movement disorder that comprises Parkinson's disease" is non-complaint since it is unclear whether Applicants intend to elect the specific disorder of "Parkinson's disease" per se or the multitude of movement symptoms/disorders claimed that occur and thus "comprise" Parkinson's disease (such as dyskinesia, akinesia, bradykinesia, etc.). Therefore, the Examiner requests that the Applicants set forth (1) the group of the invention to be examined (either I, II, or III), (2) the species of movement disorder to be examined and (3) the species of compound to which examination on the merits will be restricted.

In response to the restriction requirement under 37 C.F.R. § 1.499 the Applicants select the invention defined by Group III, without traverse, which includes claims 1, 3, 6-7, 10 and 14-18. Such election is made without prejudice to the non-elected claims in any related patent applications.

Applicants' election of a single disclosed specie of movement disorder is the specific disorder of Parkinson's disease. This election is made without prejudice to any other non-elected movement disorders in any related patent applications.

Further, with respect to the elected group III, the Examiner requires an election of a single disclosed specie of an mGluR4 receptor positive allosteric modulator. In response, the Applicants elect N-phenyl-7-(hydroxylimino)cyclo-propa[b]chromen-1a-carboxamide ("PHCCC"). This election is made without prejudice to any other non-elected mGluR4 receptor positive allosteric modulator in any related patent applications. Claims 1, 3, 6-7, 10 and 14-18 read upon this election.

Additionally, on the Office Action dated April 22, 2008 the Examiner had required an election as to whether or not the mGluR4 receptor positive allosteric modulator is administered in combination with another agent. In response, Applicants' elected the invention in which the mGluR4 receptor positive allosteric modulator is not administered in combination with another agent. Applicants maintain this election and that such election is made without prejudice to those aspects of the invention that employ agents claimed in related patent applications. Claims 1, 3, 10 and 14-18 read upon this election.


It is believed that the claims are in a condition for allowance, and a notice to that effect is respectfully requested.

If the Examiner feels that a telephone conference would be of value, he is invited to contact the undersigned counsel at the number indicated below.

The USPTO is authorized to charge Deposit Account No. 50-4644 of Bressler, Amery & Ross, P.C. for any charges in connection with this matter, including any fees related to extensions of time, which the USPTO may assume are requested if required.

Date: October 15, 2008

Respectfully submitted,



Gerard Bilotto
Reg. No. 51,474
Bressler, Amery & Ross, P.C.
17 State, Street
New York, NY 10004
Tel.: 212-510-3984
Fax: 212-425-9337
gbilotto@bressler.com